Pharmamarketeer
wet- en regelgeving

GSK’s oral nicotine spray wins divided FDA panel’s backing despite abuse risks

23 september 2019
FiercePharma

With the federal spotlight on e-cigarette use, the FDA has grown increasingly wary of nicotine-based products with risks of abuse. That didn’t stop GlaxoSmithKline from winning a recommendation for its over-the-counter nicotine spray—but the backing didn’t come easy. An FDA panel voted 9-6 to recommend GSK’s oral spray for approval for users 18 and older.

Ook interessant voor je

Medhc-fases-banner
Advertentie(s)